Nyxoah Pursues Legal Action Against Inspire Medical Systems
Nyxoah Launches Patent Infringement Lawsuit
Nyxoah, a leading medical technology company, is making headlines with the announcement of its patent infringement lawsuit against Inspire Medical Systems, Inc. This legal action focuses on Inspire's devices, specifically the Inspire IV and Inspire V, which Nyxoah claims infringe on three of its patents. As a company committed to innovation in treating Obstructive Sleep Apnea (OSA), Nyxoah is taking steps to protect its intellectual property and uphold the integrity of its pioneering solutions.
Understanding the Claims Against Inspire Medical Systems
Nyxoah has initiated this lawsuit in the United States District Court for the District of Delaware. The intellectual property at the center of the dispute includes U.S. Patent Nos. 8,700,183, 9,415,215, and 9,415,216. By seeking injunctive relief and damages from Inspire, Nyxoah is standing firm in its belief that its proprietary technology must remain protected from unauthorized use.
CEO's Commitment to Innovation
Olivier Taelman, the Chief Executive Officer of Nyxoah, expressed the company's dedication to its unique Genio® system during recent statements. According to Taelman, the Genio system differentiates itself by not relying on traditional pacemaker hardware. This system provides bilateral stimulation as well as full-body MRI compatibility, representing a significant leap in OSA treatment technology. Taelman highlighted the importance of providing physicians and patients with trustworthy alternatives that prioritize patient well-being.
Success and Feedback from the Genio System
Following its August launch, Nyxoah has received enthusiastic responses from both physicians and patients regarding the Genio system. The company is eager to expand its reach, making their advanced treatment options more accessible to those suffering from OSA. Nyxoah's mission reflects a commitment to patient care and the desire to improve quality of life for individuals managing sleep apnea.
The Genio System: A Breakthrough in Sleep Apnea Treatment
Nyxoah focuses on creating and commercializing advanced solutions for sleep apnea, with the Genio system as its flagship product. This innovative device is leadless and battery-free, utilizing hypoglossal neurostimulation therapy. As OSA can lead to serious health complications, including cardiovascular issues and increased mortality risk, the availability of effective treatment options is more crucial than ever.
Regulatory Milestones and Future Potential
Nyxoah has achieved significant milestones over the years, highlighted by the receipt of the European CE Mark in 2019 after the successful BLAST OSA study. The company went public on Euronext Brussels in September 2020, followed by a NASDAQ listing in July 2021. Positive results from the BETTER SLEEP study also led to expanded CE mark approval for the Genio system, allowing for treatment in previously contraindicated patient categories.
Recent Developments and FDA Approval
The company's momentum continued with the announcement of positive outcomes from the DREAM IDE pivotal study, culminating in U.S. FDA approval for the Genio system as a prescription-only device. Such advancements reflect Nyxoah's ongoing commitment to research, development, and the commercialization of effective therapies for sleep-disordered breathing.
Contacts for Further Information
For individuals seeking additional information, Nyxoah encourages outreach via its investor relations email. Reaching out to John Landry, the CFO, can be done at IR@nyxoah.com.
Frequently Asked Questions
What is the lawsuit about?
Nyxoah filed a lawsuit against Inspire Medical Systems for allegedly infringing on its patents associated with the Genio system and its treatment technology.
What products are involved in this lawsuit?
The lawsuit targets Inspire's Inspire IV and Inspire V devices, claiming they infringe on Nyxoah's intellectual property.
What is the Genio system?
The Genio system is a groundbreaking treatment for Obstructive Sleep Apnea that uses hypoglossal neurostimulation therapy and is leadless and battery-free.
When did Nyxoah receive FDA approval?
Nyxoah received FDA approval for the Genio system recently, confirming its status as a prescription-only treatment option.
How can I learn more about Nyxoah?
For further information, visit Nyxoah's official website or contact their investor relations via email.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.